| ［1］ |
Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis ⁃ a systematic review［J］. J Dermatolog Treat, 2021,32（1）:19⁃28.
|
| ［2］ |
Husein⁃ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response［J］. J Dermatolog Treat, 2020:1⁃7.
|
| ［3］ |
Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:e74⁃e76.
|
| ［4］ |
Russo F, Provvidenziale L, Bruzziches F,et al. Psoriasis-like eruption triggered by dupilumab Therapy［J］. Dermatitis, 2021,32（6）:e147⁃e148. doi: 10.1097/DER.0000000000000740.
|
| ［5］ |
Safa G, Paumier V. Psoriasis induced by dupilumab therapy［J］. Clin Exp Dermatol, 2019,44（3）:e49⁃e50.
|
| ［6］ |
Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report［J］. Br J Dermatol, 2021,185（2）:432⁃434.
|
| ［7］ |
Tracey EH, Elston C, Feasel P, et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab［J］. JAAD Case Rep, 2018,4（7）:708⁃710.
|
